Una Recomendación de No Hacer es una indicación de abandonar una práctica clínica de escaso valor. El escaso valor lo determina el hecho de que la práctica no reporte ningún beneficio conocido para los pacientes y/o les ponga en riesgo de sufrir daños y además pueda suponer un derroche de recursos, sanitarios y/o sociales.
Las Recomendaciones de NO Hacer incluidas en el Catálogo son las que cumplen todos estos criterios.
Para solicitar la inclusión en el Catálogo, es preciso cumplimentar el formulario.
Ver más información sobre la Iniciativa NO Hacer
Lin K, Fajardo K. US Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: evidence for the US Preventive Service Task Force reaffirmation recommendation statement. Ann Intern Med 2008;148:W20-24
Nicolle LE, Bradley S, Colgan R et al. Infectious diseases Society of American Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-654.
Antithrombotic Trialist Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1949-60
Raju N, Sobieraj-Teague M, Hirsh J et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-9.
Seshasai SRK, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes. Meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209-16.
US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150:396-404.
Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701
. American Geriatrics Society Updated Beers Criteria for potentially inappropriate medication use in older adults. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc 2012;60(4):616-31.
Gallagher P, O´Mahony D. STOPP (Screening Tool of Older Persons´potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers´criteria Age and Ageing 2008;208:673-678.
Garfinkel D, Mangin D. Feasibility Study of a Systematic Approach for discontinuation of multiple medications in older adults. Addressing polipharmacy. Arch Intern Med 2010;170:1648-1654.
. Porapakkham P, Zimmet H, Billah B, Krum H. B-Type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med 2010;170:507-514.
McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128(16):e240-327
Mancia G, Fagard R, Narkiewizc K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357
.Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-52.
Kdigo 2012. Clinical Practice Guideline for the Evaluation and management of chronic kidney disease. Kidney International 2013;84(3):622-3
Sharen decision-making in the appropriate initiation of and withdrawal from dialysis. Clinical Practice Guideline. Second Edition. Renal Physician Association Rockville, Maryland Octubre 2010.
Ogihara T, Saruta T, Rakugi H et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56:196-202
JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115-2127.
Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Eng J Med 2013;369(20):1892-1903
. Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for hearth failure. Cochrane Database Syst Rev 2012;4:CD003040.
Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD et al. Cardio renal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Eng J Med 2012;367(23):2204-13
US Food and Drug Administration. FDA drug safety communication: New warning and contraindication for Blood pressure medicines containing aliskiren (Tekturna).
[http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm.]
National Institute Clinical Excellence (NICE) 2011. Anaemia management in people with Chronic Kidney disease. Clinical Guideline (CG114). Updated guideline in 2015 (CG8).
Grupo de trabajo de la Guía de Práctica Clínica sobre Infección de Tracto Urinario en la Población Pediátrica. Guía de Práctica Clínica sobre Infección del Tracto Urinario en la Población Pediátrica. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Instituto Aragonés de Ciencias de la Salud; 2011. Guías de Práctica Clínica en el SNS: I+CS No 2009/01.